These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28434043)

  • 1. Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial.
    Herrlinger U; Schäfer N; Fimmers R; Griesinger F; Rauch M; Kirchen H; Roth P; Glas M; Bamberg M; Martus P; Thiel E; Korfel A; Weller M
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1815-1821. PubMed ID: 28434043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive functions in primary CNS lymphoma after single or combined modality regimens.
    Correa DD; Shi W; Abrey LE; Deangelis LM; Omuro AM; Deutsch MB; Thaler HT
    Neuro Oncol; 2012 Jan; 14(1):101-8. PubMed ID: 22013168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.
    Korfel A; Thiel E; Martus P; Möhle R; Griesinger F; Rauch M; Röth A; Hertenstein B; Fischer T; Hundsberger T; Mergenthaler HG; Junghanß C; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Roth P; Bamberg M; Pietsch T; Weller M
    Neurology; 2015 Mar; 84(12):1242-8. PubMed ID: 25716362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.
    Hottinger AF; DeAngelis LM; Yahalom J; Abrey LE
    Neurology; 2007 Sep; 69(11):1178-82. PubMed ID: 17846417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
    Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
    Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life after whole brain radiotherapy compared with radiosurgery of the tumor bed: results from a randomized trial.
    Kepka L; Tyc-Szczepaniak D; Osowiecka K; Sprawka A; Trąbska-Kluch B; Czeremszynska B
    Clin Transl Oncol; 2018 Feb; 20(2):150-159. PubMed ID: 28616720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive status and quality of life after treatment for primary CNS lymphoma.
    Harder H; Holtel H; Bromberg JE; Poortmans P; Haaxma-Reiche H; Kluin-Nelemans HC; Menten J; van den Bent MJ
    Neurology; 2004 Feb; 62(4):544-7. PubMed ID: 14981168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life in patients with limited (1-3) brain metastases undergoing stereotactic or whole brain radiotherapy : A prospective study of the DEGRO QoL working group.
    Steinmann D; Vordermark D; Gerstenberg W; Aschoff R; Gharbi N; Müller A; Schäfer C; Theodorou M; Wypior HJ; Geinitz H;
    Strahlenther Onkol; 2020 Jan; 196(1):48-57. PubMed ID: 31418046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal cognitive assessment in patients with primary CNS lymphoma treated with induction chemotherapy followed by reduced-dose whole-brain radiotherapy or autologous stem cell transplantation.
    Correa DD; Braun E; Kryza-Lacombe M; Ho KW; Reiner AS; Panageas KS; Yahalom J; Sauter CS; Abrey LE; DeAngelis LM; Omuro A
    J Neurooncol; 2019 Sep; 144(3):553-562. PubMed ID: 31377920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.
    Caissie A; Nguyen J; Chen E; Zhang L; Sahgal A; Clemons M; Kerba M; Arnalot PF; Danjoux C; Tsao M; Barnes E; Holden L; Danielson B; Chow E
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1238-45. PubMed ID: 22172909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous intrathecal injection therapy of methotrexate is a therapeutic option in primary CNS lymphoma.
    Otani R; Yamada R; Kushihara Y; Inazuka M; Shinoura N
    J Clin Neurosci; 2019 Nov; 69():26-30. PubMed ID: 31466902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive functions in survivors of primary central nervous system lymphoma.
    Correa DD; DeAngelis LM; Shi W; Thaler H; Glass A; Abrey LE
    Neurology; 2004 Feb; 62(4):548-55. PubMed ID: 14981169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial-brain radiotherapy for primary central nervous system lymphoma: multi-institutional experience.
    Iwabuchi M; Shibamoto Y; Sugie C; Ayakawa S; Ogino H; Baba F
    J Radiat Res; 2016 Mar; 57(2):164-8. PubMed ID: 26661856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is reduced-dose whole-brain radiotherapy also feasible in primary CNS lymphoma for curative or salvage purpose?
    Ko MK; Kwak YK; Choi BO; Jeun SS; Park JS; Ahn S; Song JH
    J Neurooncol; 2023 Nov; 165(2):321-328. PubMed ID: 37964132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy.
    Dabaja BS; McLaughlin P; Ha CS; Pro B; Meyers CA; Seabrooke LF; Wilder RB; Kyritsis AP; Preti HA; Yung WK; Levin V; Cabanillas F; Cox JD
    Cancer; 2003 Sep; 98(5):1021-8. PubMed ID: 12942571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
    Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118.
    Corn BW; Moughan J; Knisely JP; Fox SW; Chakravarti A; Yung WK; Curran WJ; Robins HI; Brachman DG; Henderson RH; Mehta MP; Movsas B
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):71-8. PubMed ID: 18164829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and opportunities in primary CNS lymphoma: A systematic review.
    Kerbauy MN; Moraes FY; Lok BH; Ma J; Kerbauy LN; Spratt DE; Santos FP; Perini GF; Berlin A; Chung C; Hamerschlak N; Yahalom J
    Radiother Oncol; 2017 Mar; 122(3):352-361. PubMed ID: 28104300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma.
    Doolittle ND; Korfel A; Lubow MA; Schorb E; Schlegel U; Rogowski S; Fu R; Dósa E; Illerhaus G; Kraemer DF; Muldoon LL; Calabrese P; Hedrick N; Tyson RM; Jahnke K; Maron LM; Butler RW; Neuwelt EA
    Neurology; 2013 Jul; 81(1):84-92. PubMed ID: 23685932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.